KBC Group
CSTL icon

KBC Group’s Castle Biosciences CSTL Stock Holding History

KBC Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$860K Sell
36,042
-890
-2% -$19.8K ﹤0.01% 750
2026
Q1 		$907K Buy
+36,932
New +$1.21M ﹤0.01% 732

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KBC Group's CSTL Position: Q2 2026 in Review

KBC Group reduced its Castle Biosciences (CSTL) stake by 2.4% in Q2 2026, selling an estimated $19.8K and leaving 36,042 shares worth $860K. The position accounts for ﹤0.01% of the portfolio, ranked #750.

KBC Group first reported a position in CSTL in Q1 2026 and has held it in 2 quarters since. The position peaked at $907K in Q1 2026. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • KBC Group held 36,042 shares of Castle Biosciences worth $860K as of Q2 2026.
  • KBC Group sold 890 Castle Biosciences shares in Q2 2026, an estimated $19.8K.
  • Castle Biosciences made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #750 holding.
  • KBC Group first reported a position in Castle Biosciences in Q1 2026 and has held it in 2 quarters since.
  • KBC Group's Castle Biosciences position peaked at $907K in Q1 2026.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.